REGENERON PHARMACEUTICALS INC. - COMMON STOCK
934.60
02-May-24 12:21:29
15 minutes delayed
Stocks
+31.12
+3.44%
Today's range
891.30 - 938.39
ISIN
N/A
Source
NASDAQ
-
Regeneron Reports First Quarter 2024 Financial and Operating Results
02 May 2024 06:30:00 By Nasdaq GlobeNewswire
-
29 Apr 2024 07:00:18 By Nasdaq GlobeNewswire
-
25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
-
24 Apr 2024 10:05:18 By Nasdaq GlobeNewswire
-
22 Apr 2024 17:54:01 By Nasdaq GlobeNewswire
-
07 Apr 2024 16:00:12 By Nasdaq GlobeNewswire
-
01 Apr 2024 16:05:00 By Nasdaq GlobeNewswire
-
Regeneron Provides Update on Biologics License Application for Odronextamab
25 Mar 2024 07:00:02 By Nasdaq GlobeNewswire
-
11 Mar 2024 07:00:23 By Nasdaq GlobeNewswire
-
08 Mar 2024 07:00:26 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
28 Feb 2024 09:48:56 By NetDania Notify
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
26 Feb 2024 09:48:37 By NetDania Notify
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
23 Feb 2024 09:45:04 By NetDania Notify
-
23 Feb 2024 01:00:00 By Nasdaq GlobeNewswire
-
21 Feb 2024 07:00:13 By Nasdaq GlobeNewswire
-
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16 Feb 2024 00:59:00 By Nasdaq GlobeNewswire
-
Regeneron Announces Investor Conference Presentations
06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK
02 Feb 2024 09:45:10 By NetDania Notify
-
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
02 Feb 2024 06:30:01 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >